Buprenorphine clinical trials
Buprenorphine is named as an intervention in 5 current clinical trials in our Canada, Mexico, UK, USA and France registers. 4 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Eli Lilly and Company (1). The most-studied condition is Opioid Use Disorder.
Where Buprenorphine is approved
All regulators →Of the three regulators tracked here, the first to approve Buprenorphine was the US, on 29 Dec 1981. It is approved in 3 of the 3 regulators tracked here.
- 1 EU safety letter (DHPC), latest: quality defect for Suboxone, 18 Jun 2020
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
Buprenorphine patents and exclusivity
Expiry tracker →Protections still running for marketed products containing Buprenorphine, as listed by the regulators. Expired patents and exclusivities, and discontinued products, are not shown.
- 23 listed patents; the last listed expires 22 Jun 2038 (US 10646484).
- Exclusivity M-314: Other exclusivity: updates to the prescribing information based on results of clinical studies, until 21 Feb 2028.
Reproduced from the FDA Orange Book and Purple Book (checked 8 Nov 2026) and the European Commission's Union Register of medicinal products (CC BY 4.0; the EU expiry date is calculated exactly as the Commission's register displays it). Listed patents and dates are as submitted to or published by the regulator and may not reflect litigation, invalidation, settlements, lapsed fees or later extensions. This is not legal advice or a freedom-to-operate opinion, and it does not say when a generic or biosimilar will launch.
What health systems spend on Buprenorphine
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Buprenorphine works
All drug targets →- Mu opioid receptor agonist AgonistTarget: OPRM1 opioid receptor mu 1✓ In ChEMBL and the Guide to Pharmacology
- Kappa opioid receptor agonist AgonistTarget: OPRK1 opioid receptor kappa 1✓ In ChEMBL and the Guide to Pharmacology
- Back painPhase 3
- AnxietyPhase 3
- Cancer painPhase 3
- Chronic back painPhase 3
- Cocaine abusePhase 3
- Depressive disorderPhase 3
- Heroin dependencePhase 3
- Major depressive disorderPhase 3
- Neonatal abstinence syndromePhase 3
- Opioid use disorderPhase 3
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL511142, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 1670, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
NICE appraisals of Buprenorphine
All NICE appraisals →NICE, which decides whether the NHS in England should fund new medicines, has published 1 technology appraisal of Buprenorphine. 1 is current, and 1 of it recommends it for at least some patients.
| Appraisal | NICE recommendation | Published | Status |
|---|---|---|---|
| Methadone and buprenorphine for the management of opioid dependence NICE TA114 | Recommended | 24 Jan 2007 | Current |
NICE decisions apply to the NHS in England. In Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics. Titles, categories and dates link to the guidance on nice.org.uk. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
Patient leaflets for Buprenorphine
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 32 products on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- EUEuropean Union: Buprenorphine Neuraxpharm, BuvidalEMA product information: package leaflet and summary of product characteristics in every EU language.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Buprenorphine
5 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Buprenorphine across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Licensed in Ireland (HPRA)
32 single-substance products containing Buprenorphine on the HPRA medicines list.
- BuTrans 10 micrograms/hour transdermal patchMundipharma Pharmaceuticals Limited · PA1688/002/002 · Marketed
- BuTrans 15 microgram/hour transdermal patchMundipharma Pharmaceuticals Limited · PA1688/002/004 · Marketed
- BuTrans 20 micrograms/hour transdermal patchMundipharma Pharmaceuticals Limited · PA1688/002/003 · Marketed
- BuTrans 5 micrograms/hour transdermal patchMundipharma Pharmaceuticals Limited · PA1688/002/001 · Marketed
- Reletrans 10 micrograms/hour Transdermal PatchesRowex Limited, · PA0711/236/002 · Marketed
Supply shortages
- Buprenorphin AWD Matrix 70 Mikrogramm/h Transdermales PflasterGermany (BfArM) · Other reason · 14 Mar 2024 to 18 Dec 2026
- Buprenorphin AWD Matrix 70 Mikrogramm/h Transdermales PflasterGermany (BfArM) · Other reason · 14 Mar 2024 to 18 Dec 2026
- Buprenorphin AWD Matrix 70 Mikrogramm/h Transdermales PflasterGermany (BfArM) · Other reason · 14 Mar 2024 to 18 Dec 2026
- Buprenorphin AWD Matrix 52,5 Mikrogramm/h Transdermales PflasterGermany (BfArM) · Other reason · 14 Mar 2024 to 18 Dec 2026
- Buprenorphin AWD Matrix 52,5 Mikrogramm/h Transdermales PflasterGermany (BfArM) · Other reason · 14 Mar 2024 to 18 Dec 2026
- Buprenorphin AWD Matrix 52,5 Mikrogramm/h Transdermales PflasterGermany (BfArM) · Other reason · 14 Mar 2024 to 18 Dec 2026
+ 5 more German shortage notices.
Conditions studied with Buprenorphine
6 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Eli Lilly and Company | 1 |
| Centre Hospitalier Universitaire de Nīmes | 1 |
| Duke University | 1 |
| Pouya Azar | 1 |
| NYU Langone Health | 1 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Canada | 3 | 3 |
| Clinical trials in Mexico | 2 | 1 |
| Clinical trials in UK | 1 | 1 |
| Clinical trials in USA | 1 | 1 |
| Clinical trials in France | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Buprenorphine trials
How many clinical trials are testing Buprenorphine?
5 current trials in our Canada, Mexico, UK, USA and France registers name Buprenorphine as a drug or biological intervention, as of the registry sync on 13 November 2026. Completed and withdrawn studies are not counted.
Are Buprenorphine trials recruiting patients?
Yes. 4 of the 5 trials are recruiting: 3 with sites in Canada, 1 with sites in Mexico, 1 with sites in UK, 1 with sites in USA and 1 with sites in France. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Buprenorphine clinical trials?
Eli Lilly and Company (1), Centre Hospitalier Universitaire de Nīmes (1), Duke University (1) and Pouya Azar (1), among 5 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Is Buprenorphine licensed in Ireland?
Yes. The HPRA medicines list includes 32 single-substance products containing Buprenorphine, for example BuTrans 10 micrograms/hour transdermal patch (Mundipharma Pharmaceuticals Limited). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Is there a Buprenorphine shortage?
The registers we track list 11 entries for Buprenorphine: 11 German notices. Shortages are product- and country-specific; check with a pharmacist.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Buprenorphine works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Buprenorphine works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Buprenorphine (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 13 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.